ArticleIranian journal of basic medical sciences2026
Beyond bioactivity: Chitosan macromolecular coatings on titanium surfaces drive osseointegration and immune suppression through targeted epigenetic regulation.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To address titanium (Ti) implant failures caused by inadequate osseointegration and persistent inflammation by developing a novel dual-action coating. This coating utilizes a chitosan (CH) matrix to deliver epigenetic pharmaceuticals, 5-azacytidine (AZ) and trichostatin A (TR), onto Ti surfaces (AZ/TR-CH@TI). Materials and Methods: Coating morphology and successful drug integration were validated via FTIR and SEM. Drug release kinetics were evaluated in physiological (pH 7.4) and inflammatory (pH 5.5) conditions over 48 hr. In vitro assessments utilizing MG63 osteoblast-like cells evaluated biocompatibility, anti-inflammatory responses, and osteogenic differentiation using real-time gene expression analysis, functional assays (alkaline phosphatase, Alizarin red), and immunofluorescence. Results: The composite exhibited an intelligent, pH-responsive controlled drug release. AZ/TR-CH@TI significantly enhanced biocompatibility, achieving 124.6% cell proliferation and 89.3% wound closure compared to uncoated controls. Gene expression analysis demonstrated potent anti-inflammatory effects, with TNF-α and IL-6 reduced to 0.31- and 0.35-fold, respectively. Concurrently, it augmented osteogenesis, up-regulating RUNX2 (2.60-fold), BMP2 (4.87-fold), and type-1 collagen (4.15-fold). Assays unequivocally validated comprehensive osteogenic differentiation and significant mineralization. Conclusion: This macromolecular epigenetic drug-loaded CH coating effectively mitigates inflammation while simultaneously stimulating bone formation. The AZ/TR-CH@TI system presents a highly promising therapeutic approach to improve Ti osseointegration for clinical orthopaedic and dental applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.